psalexa
logo

Botulism Therapeutics Pipeline Analysis

Botulism Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11202
Available Format:

Botulism is a rare illness caused by a toxin that attack a body’s nerves. Botulism toxin is made by Clostridium botulinum and sometimes Clostridium butyricum and Clostridium baratii bacteria. The symptoms of botulism usually start with weakness of the muscles that control the eyes, face, mouth, and throat. This weakness can further spread to the neck, arms, torso, and legs. Botulism can also weaken the muscles involved in breathing, which can lead to difficulty breathing and can be fatal. The bacteria that make botulinum toxin are found naturally in many places, but it is rare for them to make people sick. It has been observed that more than 90% of the patients with botulism have 3-5 of the following signs or symptoms, nausea, vomiting, dysphagia, diplopia, dilated/fixed pupils, extremely dry mouth unrelieved by drinking fluids.

Some of the drug candidates in the botulism pipeline include, but are not limited to, Botulinum toxin A topical, Botulinum toxin A and Botulinum toxin intravesicular. Some of the companies having drugs in the botulism pipeline includes CytoDel LLC, Hawaii Biotech Inc, Microbiotix Inc. and XOMA Corp.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry